CLERON 250MG FILM COATED TABLETS

Land: Zypern

Sprache: Griechisch

Quelle: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Gebrauchsinformation Gebrauchsinformation (PIL)
01-03-2021
Fachinformation Fachinformation (SPC)
15-03-2018

Wirkstoff:

CLARITHROMYCIN

Verfügbar ab:

DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629

ATC-Code:

J01FA09

INN (Internationale Bezeichnung):

CLARITHROMYCIN

Dosierung:

250MG

Darreichungsform:

FILM COATED TABLETS

Zusammensetzung:

CLARITHROMYCIN (8000001318) 250MG

Verabreichungsweg:

ORAL USE

Verschreibungstyp:

Εθνική Διαδικασία

Therapiebereich:

CLARITHROMYCIN

Produktbesonderheiten:

Νομικό καθεστώς: Με Ιατρική Συνταγή; PACK WITH 14 TABS IN BLISTER(S) (980006801) 14 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή

Gebrauchsinformation

                                COMPARATIVE TABLE OF PIL-EN VS PIL-GR
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
CLERON 250 MG FILM-COATED TABLETS
CLERON 500 MG FILM-COATED TABLETS
clarithromycin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on
to others. It may harm them, even if their signs of illness are the
same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in the leaflet. See
section 4.
WHAT IS IN THIS LEAFLET:
1. What Cleron tablets are and what they are used for
2. What you need to know before you take Cleron tablets
3. How to take Cleron tablets
4. Possible side effects
5. How to store Cleron tablets
6. Contents of the pack and other information
1. WHAT CLERON TABLETS ARE AND WHAT THEY ARE USED FOR
ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ: ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ
ΤΟΝ ΑΣΘΕΝΉ
CLERON 250 MG ΕΠΙΚΑΛΥΜΜΈΝΑ ΜΕ ΛΕΠΤΌ ΥΜΈΝΙΟ
ΔΙΣΚΊΑ
CLERON 500 MG ΕΠΙΚΑΛΥΜΜΈΝΑ ΜΕ ΛΕΠΤΌ ΥΜΈΝΙΟ
ΔΙΣΚΊΑ
κλαριθρομυκίνη
ΔΙΑΒΆΣΤΕ ΠΡΟΣΕΚΤΙΚΆ ΟΛΌΚΛΗΡΟ ΤΟ ΦΎΛΛΟ
ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ ΠΡΙΝ
ΑΡΧΊΣΕΤΕ ΝΑ ΠΑΊΡΝΕΤΕ ΑΥΤΌ ΤΟ ΦΆΡΜΑΚΟ,
ΔΙΌΤΙ ΠΕΡΙΛΑΜΒΆΝΕΙ
ΣΗΜΑΝΤΙΚΈΣ ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΣΑΣ.

Φυλάξτε αυτό το φύλλο οδηγιών χρήσης.
Ίσως χρειαστεί να το
διαβάσετε ξανά.

Εάν έχετε περαιτέρω απορίες, ρωτήστε
τον γιατρό ή τον
φαρμακοποιό σας.

Η συνταγή για αυτό το φάρμακο
χορηγήθηκε αποκλειστικά για
σας. Δεν πρέπει να δώσετε το φάρμακο σε
ά
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Fachinformation

                                SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Cleron 250 mg Film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 250 mg of Clarithromycin.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets.
Cleron 250 mg Film-coated tablets are
yellow, round, concave film coated tablets, 12mm in diameter,
scored on one side and embossed with “CLERON 250”.
4.
CLINICAL INFORMATION
4.1 THERAPEUTIC INDICATIONS
Consideration should be given to official guidance on the appropriate
use of antibacterial agents.
Cleron 250 mg film-coated tablets are indicated in adults and children
12 years and older.
Clarithromycin is indicated for treatment of infections caused by
susceptible organisms. Indications
include:
Lower respiratory tract infections for example, acute and chronic
bronchitis, and pneumonia (see section
4.4 and 5.1 regarding Sensitivity Testing).
Upper respiratory tract infections for example, sinusitis and
pharyngitis.
Clarithromycin is appropriate for initial therapy in community
acquired respiratory infections and has
been shown to be active _in vitro_ against common and atypical
respiratory pathogens as listed in the
microbiology section.
Clarithromycin is also indicated in skin and soft tissue infections of
mild to moderate severity (e.g.
folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1
regarding Sensitivity Testing).
Clarithromycin in the presence of acid suppression effected by
omeprazole or lansoprazole is also
indicated for the eradication of _H. pylori_ in patients with duodenal
ulcers. See Dosage and Administration
section.
1
Clarithromycin is usually active against the following organisms in
vitro:
Gram-positive Bacteria: _Staphylococcus aureus_ (methicillin
susceptible); _Streptococcus pyogenes_ (Group
A beta-haemolytic streptococci); alpha-haemolytic streptococci
(viridans group_); Streptococcus_
_(Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria
monocytogenes_.
Gram-negative
Bacter
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Dokumente in anderen Sprachen

Fachinformation Fachinformation Englisch 29-03-2021

Suchen Sie nach Benachrichtigungen zu diesem Produkt